INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors
BENSALEM, Pa .– (BUSINESS WIRE) – Law Offices of Howard G. Smith announced that a class action lawsuit was filed on behalf of investors purchasing the securities of Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) between February 2nd Purchased in 2021 and June 10th, 2021 inclusive (the “Class Period”). Ocugen investors have until August 16, 2021 to file a lead plaintiff motion.
Investors suffering losses on their Ocugen investments are advised to contact the Howard G. Smith law firms at 888-638-4847 or email [email protected] to determine their legal rights in this class action lawsuit to discuss.
Ocugen is a biopharmaceutical company. Under an agreement with Bharat Biotech, Ocugen has exclusive rights to develop, manufacture and commercialize COVAXIN, a vaccine candidate for COVID-19.
On June 10, 2021, Ocugen announced that it would file a Biologics License Application (“BLA”) for COVAXIN, which has a longer approval process than an Emergency Authorization (“EUA”) application and that it is expected to have an additional one conduct clinical trial attempt to support the submission.
As a result of this news, the company’s share price fell $ 2.62 per share, or 28%, to close at $ 6.69 per share on June 10, 2021, hurting investors.
The lawsuit filed alleges that, during the class action period, defendants made materially false and / or misleading statements and failed to disclose material adverse facts about the company’s business, operations and prospects. In particular, Defendants have failed to disclose to investors that: (1) the information presented to the FDA was insufficient to support an EEA; (2) Ocugen would not file an emergency clearance with the FDA; and (3) as a result, Defendants’ statements about its business, operations and prospects were materially false and misleading and / or were inadequate at all relevant times.
If you have purchased Ocugen securities, have information about these claims, or have any questions about this announcement or your rights or interests in relation to these matters, please contact Howard G. Smith, Esquire, Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by phone at (215) 638-4847, toll free at (888) 638-4847, or by email at [email protected], or visit our Website at www.howardsmithlaw.com.
This press release may be viewed as a solicitation in some jurisdictions subject to applicable laws and ethical rules.